Adrenomedullin in heart failure: pathophysiology and therapeutic application by Voors, A.A. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/206328
 
 
 
Please be advised that this information was generated on 2020-09-08 and may be subject to
change.
European Journal of Heart Failure (2019) 21, 163–171 REVIEW
doi:10.1002/ejhf.1366
Adrenomedullin in heart failure:
pathophysiology and therapeutic application
Adriaan A. Voors1*, Daan Kremer1, Christopher Geven2, Jozine M. ter Maaten1,
Joachim Struck3,4, Andreas Bergmann3,4, Peter Pickkers2, Marco Metra5,
Alexandre Mebazaa6, Hans-Dirk Düngen7, and Javed Butler8
1Department of Cardiology, University of Groningen, Groningen, The Netherlands; 2Department of Intensive Care Medicine, Radboud Center for Infectious Diseases, Radboud
University Medical Center, Nijmegen, The Netherlands; 3Sphingotec GmbH, Hennigsdorf, Germany; 4Adrenomed AG, Hennigsdorf, Germany; 5Department of Medical and
Surgical Specialties, Radiological Sciences and Public Health, Institute of Cardiology, University of Brescia, Brescia, Italy; 6APHP, Hôpitaux Universitaires Saint-Louis Lariboisière;
INI-CRCT, University Paris Diderot, Paris, France; 7Department of Cardiology, Charité Universitätsmedizin, Campus Virchow-Klinikum, Berlin, Germany; and 8Division of
Cardiology, Stony Brook University, Stony Brook, NY, USA
Received 4 September 2018; revised 18 October 2018; accepted 22 October 2018 ; online publish-ahead-of-print 28 December 2018
Adrenomedullin (ADM) is a peptide hormone first discovered in 1993 in pheochromocytoma. It is synthesized by endothelial and vascular
smooth muscle cells and diffuses freely between blood and interstitium. Excretion of ADM is stimulated by volume overload to maintain
endothelial barrier function. Disruption of the ADM system therefore results in vascular leakage and systemic and pulmonary oedema. In
addition, ADM inhibits the renin–angiotensin–aldosterone system. ADM is strongly elevated in patients with sepsis and in patients with acute
heart failure. Since hallmarks of both conditions are vascular leakage and tissue oedema, we hypothesize that ADM plays a compensatory role
and may exert protective properties against fluid overload and tissue congestion. Recently, a new immunoassay that specifically measures
the biologically active ADM (bio-ADM) has been developed, and might become a biomarker for tissue congestion. As a consequence,
measurement of bio-ADM might potentially be used to guide diuretic therapy in patients with heart failure. In addition, ADM might be used
to guide treatment of (pulmonary) oedema or even become a target for therapy. Adrecizumab is a humanized, monoclonal, non-neutralizing
ADM-binding antibody with a half-life of 15 days. Adrecizumab binds at the N-terminal epitope of ADM, leaving the C-terminal side intact
to bind to its receptor. Due to its high molecular weight, the antibody adrecizumab cannot cross the endothelial barrier and consequently
remains in the circulation. The observation that adrecizumab increases plasma concentrations of ADM indicates that ADM-binding by
adrecizumab is able to drain ADM from the interstitium into the circulation. We therefore hypothesize that administration of adrecizumab
improves vascular integrity, leading to improvement of tissue congestion and thereby may improve clinical outcomes in patients with acute
decompensated heart failure. A phase II study with adrecizumab in patients with sepsis is ongoing and a phase II study on the effects of
adrecizumab in patients with acute decompensated heart failure with elevated ADM is currently in preparation.
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Introduction
Hospitalizations for heart failure are a major burden for patients,
relatives, health care providers and society. Despite improve-
ments in therapy for patients with heart failure with a reduced
ejection fraction, we have not been able to reduce the risk
of heart failure readmissions after a hospitalization for worsening
heart failure. Approximately 35–50% of heart failure patients are
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.. rehospitalized within 6months of discharge, making heart failure
the most frequent diagnosis for 30-day readmissions and incurring
billions in costs.1–3 Therefore, preventing hospital (re-)admissions
is recognized as a major unmet need in the treatment of heart
failure.
Risk prediction models have become reasonably accurate for
predicting (cardiovascular) mortality, but models to predict hospi-
tal (re-)admissions performmuch worse.4 Given its poor predictive
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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value, identifying patients for clinical trials who are at high risk
of hospital (re-)admission is difficult. Therefore, there is a need
for markers to better identify patients who are at high risk for
heart failure (re-)hospitalization. Preferably, these markers should
reflect a process that can be pathophysiologically linked to wors-
ening heart failure.
Several studies have consistently shown that the main rea-
son for (re-)hospitalization for worsening heart failure is related
to dyspnoea or breathlessness, mainly caused by pulmonary
congestion.5–9 The great majority of patients are treated with
loop diuretics to relieve congestion, but a large number of patients
are discharged without losing body weight and with persistent
signs of congestion.7,9–11 This is particularly true when patients
are discharged early and in patients without weight loss despite
loop diuretic therapy. Consequently, studies have shown higher
risks of hospital readmission in patients with a shorter duration
of hospitalization, with a poor diuretic response, and with residual
signs of congestion at discharge. Therefore, markers that reflect
residual congestion might be useful to identify patients that are
both epidemiologically and pathophysiologically at higher risk of
hospital (re-)admission. Currently, clinical signs at physical exam-
ination such as oedema, rales and jugular venous pressure are
the mainstay for assessment of congestion. However, this exam-
ination is often not performed in clinical practice, is very depen-
dent on the clinician’s skills,12 has a low interrater reliability and
specificity13–15 and is subjective due to the lack of standardized
metrics or (de)congestion scores.16 In view of the high incidence
of rehospitalization, clinical assessment of congestion is clearly
insufficient. What clinicians therefore need is an easy-to-use sur-
rogate for the assessment of a patient’s (de)congestion status that
may facilitate clinical decision making. The use of biomarkers for
this purpose is attractive, since they are objective, easily avail-
able and have a known sensitivity and specificity. While by many
heart failure clinicians natriuretic peptides are regarded as the
main biomarker for congestion, recent studies show that there
are several limitations in the use of natriuretic peptides as mark-
ers of congestion.17 Since natriuretic peptides reflect stretch and
pressure of the heart, they mainly reflect intravascular volume
overload, but do not reflect tissue and interstitial fluid. There-
fore, better and more specific markers for tissue congestions
are needed.
Adrenomedullin: an introduction
Adrenomedullin (ADM) is a peptide hormone discovered in 1993
by Kitamura et al.18 ADM is a 52 amino acid peptide, contain-
ing a ring structure and a C-terminal amide, both of which are
essential for binding to ADM receptors. The ADM gene is located
on chromosome 11 and consists of four exons.19 One of the
key determinants for biological activity of ADM is the group
of receptor activity-modifying proteins (RAMP). The combina-
tion of RAMP 2 or 3 with the calcitonin receptor-like receptor
(CRLR) confers specificity of the receptor for ADM, and thus
both RAMPs and CRLR are key in ADM expression.20–25 While
ADM was first discovered in pheochromocytoma originating from ..
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.. the adrenal medulla (hence the name ‘adrenomedullin’), further
investigation showed that it was synthesized by many other tis-
sues/cells, especially endothelial and vascular smooth muscle cells,
and due to its small size (6 kDa) diffuses freely between blood and
interstitium.26,27 By proteolytic fragmentation of the pro-hormone
(pro-ADM), a glycine-extended, inactive ADM is formed, which
subsequently is enzymatically converted from ADM-glycine to the
biologically active ADM-amide. ADM receptors and binding sites
are widespread in the body, but cardiovascular and lung tissues have
highest density of these binding sites.28 The in vivo half-life of ADM
is approximately 22min.29 ADM is assumed to mainly be metab-
olized by neutral endopeptidase, also known as neprilysin30 – a
molecule that clinicians might recognize from the recent beneficial
findings with sacubitril/valsartan as a novel treatment for patients
with heart failure.31 Sacubitril is a neprilysin inhibitor, and thus is
supposed to inhibit breakdown of ADM and several other peptide
hormones. An additional mechanism by which ADM is cleared is
through binding with its receptors and subsequent internalization
and degradation.32,33
Vascular effects of adrenomedullin
The most recognized function of ADM is vasodilatation in both
vascular resistance and capacitance vessels. ADM lowers blood
pressure, yet increases blood flow.18,34 Even low doses induce
vasodilatation, indicating that the plasma levels of ADM under
conditions such as heart failure are in the range that directly affect
vascular tone.34
Beside vasodilatation, ADM seems to play an important role
in preservation of endothelial integrity. ADM expression can be
induced by various stimuli, one of them being volume overload,
and increased plasma ADM reflects excessive fluid volume.35 This
is most likely the consequence of a counteracting response, as
the ADM-induced stabilization of endothelial barrier function is
thought to limit tissue fluid overload. Indeed, disruption of the
ADM system results in vascular leakage and systemic and pul-
monary oedema.36–38 Also the role of the ADM–RAMP 2 system
has been investigated. Mice lacking the gene encoding for RAMP
2 showed enhanced vascular permeability and systemic oedema.36
Similarly, mice with a conditional knock-out of ADM in endothelial
cells revealed increased vascular permeability in comparison with
wild-type littermates.39
Further support for the effects of ADM in maintaining vas-
cular integrity comes from experimental studies showing that
experimental overexpression of ADM inhibits systemic and pul-
monary vascular leakage in animals.40–42 For example, in a rat
model of Staphylococcus aureus-toxin induced systemic inflam-
mation, accompanied by extensive vascular leakage, ADM infu-
sion protected endothelial barrier function via cyclic adenosine
monophosphate (cAMP) elevation.40 Also, ADM dose-dependently
reduced experimentally induced endothelial hyperpermeability of
cultured human umbilical vein endothelial cell and porcine pul-
monary artery endothelial cell monolayers.41 Suppression of ADM
contributes to vascular leakage and altered epithelial repair during
asthma.42 In two animal models, intranasal ADM completely atten-
uated the acute-induced airway hyper-responsiveness and mucosal
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Simplistic representation of the mode of action of
intravascular vs. interstitial adrenomedullin. (1) Adrenomedullin
present within the blood vessels improved vascular integrity,
thereby putatively reducing vascular permeability. (2)
Adrenomedullin present in the interstitium acts on the vas-
cular smooth muscle cells and causes dilatation of the vascular
resistance and capacitance vessels.
plasma leakage.42,43 ADM acts on several pathways in order to sta-
bilize the endothelial barrier, including the cAMP/protein kinase
A (PKA) pathway that inhibits RhoA/ROCK and reduces subse-
quent myosin light chain kinase-induced actomyosin contraction
(the ‘pulling forces’ exerted on endothelial cell junctions), as well
as the cAMP/PKA and possibly the PI3K/Akt pathway to pro-
mote production of (protective) cortical actin and stabilization of
the VE-cadherin/𝛽-catenin complex (part of adherens junctions).44
Finally, ADM inhibits the renin–angiotensin–aldosterone system.45
Although ADM increases plasma renin activity, it induces reduc-
tions in the aldosterone/plasma renin activity ratio and atten-
uates angiotensin II-induced aldosterone secretion. In addition,
ADM is upregulated by angiotensin II, and protects against car-
diac hypertrophy and renal damage induced by angiotensin II.
Altogether, it is suggested that ADM acts as a functional antag-
onist to angiotensin II, hereby inhibiting aldosterone secretion
and thus compensating for renin–angiotensin–aldosterone system
escalation.
In summary, vasodilatation and maintaining vascular integrity are
the two most important functions of ADM. Importantly, the effects
of ADM depend on its location. ADM is present both intravas-
cular and in the interstitium. Its mode of action intravascular as
opposed to the interstitium is depicted in Figure 1. Intravascu-
lar ADM is thought to improve vascular integrity and decrease
vascular permeability through its effects on endothelial cells. Inter-
stitial ADM however is thought to cause vasodilatation by acting
on vascular smooth muscle cells, in an endothelium-independent
mechanism. Note that endothelial-dependent pathways have also
been described, although it remains unknown to what extent each
pathway is involved in vivo in humans.46–48 ..
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.. Adrenomedullin is elevated
in heart failure and related
to congestion and clinical
outcome in heart failure
In healthy humans, ADM circulates in the plasma in low concen-
trations. In 1995, it was first reported that ADM levels were ele-
vated in heart failure.49 Plasma ADM concentration was 13 pg/mL
in healthy subjects and 3–4 times higher in patients with chronic
heart failure.49 The observation that ADM levels decreased after
treatment with diuretics and digitalis led to the assumption that
‘volume expansion and an activated sympathetic nervous system
may be associated with this increase and that plasma ADM lev-
els change in response to the pathophysiologic changes of heart
failure.’50 After this, many studies have shown elevated levels of
ADM in patients with heart failure. In addition, several studies
found a strong association between higher levels of ADM and
adverse clinical outcome.51,52 The majority of these studies used a
stable part of the ADM precursor peptide, mid-regional pro-ADM
(MR-proADM).53 The drawback to this assay, however, is that it
measures a stable fragment of a non-functional ADM pro-peptide,
and therefore does not distinguish between the biologically active
amidated ADM and the non-functional ADM variant containing a
glycine-extended C-terminal residue. Recently, a new immunoas-
say that specifically measures biologically active ADM (bio-ADM)
has been developed.53 Plasma bio-ADM was measured in 246
patients admitted at the emergency department with suspicion of
acute heart failure.54 Plasma bio-ADM concentrations were higher
among patients who experienced a cardiovascular event [median
80.5 pg/mL; interquartile range (IQR) 53.7–151.5 pg/Ml] compared
with those who did not (median 54.4 pg/mL; IQR 43.4–78.4 pg/mL)
(P < 0.01). After adjusting for the other biomarkers, plasma
bio-ADM remained a strong predictor of a cardiovascular event.54
Another study showed that bio-ADM was a marker of impaired
haemodynamics, organ dysfunction, and poor prognosis in patients
with cardiogenic shock.55 We recently studied the clinical cor-
relation and prognostic value of serial measurements of plasma
bio-ADM levels in 1562 patients admitted for acute decompen-
sated heart failure.56 We showed that plasma bio-ADM had the
strongest association with clinically assessed congestion during
hospital admission for acute decompensated heart failure. More-
over, bio-ADM was a better predictor of residual congestion than
any other individual baseline variable. In patients with clinical signs
of residual congestion 7 days after hospital admission, bio-ADM
levels were high at baseline and remained high throughout the
first week of hospitalization. This in contrast to brain natriuretic
peptide (BNP) levels, which decreased in all patients irrespec-
tive of the presence and degree of residual congestion. Finally,
plasma bio-ADM concentrations, both at baseline and at day 7,
provided significant added predictive value for 60-day heart failure
rehospitalization, even after adjustment for a pre-defined 11-item
rehospitalization risk model, residual congestion by day 7 and BNP
at day 7.
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Bio-adrenomedullin (ADM) as a marker and inhibitor of tissue congestion. Brain natriuretic peptide (BNP) as a marker and inhibitor
of intravascular congestion.
Rationale for bio-adrenomedullin
as a biomarker for tissue
congestion
Adrenomedullin is a vasoactive peptide that is increased in patients
that are volume overloaded. Main functions of ADM are vasodi-
latation and to maintain vascular integrity and decrease vascular
leakage. Elevated levels are found in heart failure, but ADM is par-
ticularly elevated in patients with septic shock. A common factor
between both diseases is vascular leakage and organ hypoperfusion.
In heart failure, higher levels of ADM are associated with more
severe heart failure, and are the strongest predictor of (residual)
congestion in patients with acute decompensated heart failure.
Increased ADM concentrations have been associated with impaired
clinical outcome in several studies of patients with heart failure. In
a recent study, higher levels of bio-ADM were independently asso-
ciated with a higher risk of hospital readmissions.56 We therefore
propose the following concept, as depicted in Figure 2. We propose
that higher bio-ADM levels reflect residual tissue congestion, and
residual tissue congestion is related to worse outcome after dis-
charge, and a higher likelihood for frequent hospital readmissions
in particular. Therefore, such a measurement might guide physi-
cians to treat certain patients more intensively, and this might also
facilitate discharge decisions.
Adrenomedullin as a target
for therapy
Several pre-clinical (Table 1)57–66 and small clinical (Table 2)67–70
studies have established the effects of exogenous administration ..
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.. of ADM in heart failure. Briefly, these effects included a reduc-
tion in myocardial infarct size, cardiac myocyte apoptosis, left
ventricular remodelling (in animals) and aldosterone levels (ani-
mals and humans), while haemodynamics (in both humans and
animals) and survival (in animals) were improved. In a rat coro-
nary ligation model, ADM administration during the early period
of a myocardial infarction improved survival and ameliorated pro-
gression of left ventricular remodelling and heart failure.62 Similar
results were found in another study where chronic administra-
tion of ADM attenuated transition from left ventricular hyper-
trophy to heart failure in rats.60 In a case series of seven acute
heart failure patients with dyspnoea and pulmonary congestion, the
effects of long-term intravenous administration of ADM in acute
decompensated heart failure were studied. ADM infusion signifi-
cantly reduced mean arterial pressure, pulmonary arterial pressure
and systemic and pulmonary vascular resistance without changing
heart rate, and increased cardiac output for most time-points com-
pared with those at baseline.71 In another small study of seven
chronic heart failure patients and seven healthy subjects, ADM sig-
nificantly decreased mean arterial pressure and increased heart
rate in the healthy volunteers.68 In patients with heart failure, ADM
also decreased mean arterial pressure and increased heart rate, but
to a much lesser degree. ADM markedly increased cardiac index
while decreasing pulmonary capillary wedge pressure.68
Taken together, these data consistently show that ADM induces
beneficial haemodynamic, hormonal and myocardial changes in
both experimental models and patients with heart failure. These
effects are likely related to the vasodilatory properties of intravas-
cular ADM, although other pathways may also be involved. Many
vasodilators have been studied in acute and chronic heart failure
with mixed results. Therefore, it would be more interesting to be
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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.. able to stimulate the effects of ADM on endothelial permeability,
and to prevent decreases in blood pressure, since this might be
deleterious in patients with worsening heart failure.
Adrecizumab for the treatment
of heart failure and sepsis
Adrecizumab is a humanized, monoclonal, non-neutralizing anti-
body against the N-terminus of ADM. It has a half-life of 15 days
when administered by a single intravenous infusion. The mode
of action of adrecizumab is presented in Figure 3. Administration of
adrecizumab leads to a dose-dependent increase in plasma ADM
bound to the administered antibody. The increase occurs within
a few minutes and is not caused by induction of de-novo synthesis,
because concentrations of MR-proADM are not increased (an inac-
tive peptide fragment originating from the same precursor as ADM,
which is synthesized in a 1:1 ratio). It is hypothesized that translo-
cation of pre-existing ADM accounts for the observed increase in
circulating ADM.72 Briefly, circulating adrecizumab cannot leave the
blood compartment due to its high molecular weight (160 kDa),
whereas ADM (with a much lower molecular weight of 6 kDa) can
freely cross the endothelial barrier between the interstitium and
the circulation.55 Binding of ADM by adrecizumab (present in the
circulation in a large excess over ADM) prevents ADM from leav-
ing the blood vessel, effectively ‘trapping’ ADM in the circulation.
In addition, adrecizumab may translocate ADM from the intersti-
tium into the circulation. Because adrecizumab is a non-neutralizing
antibody, the net effect is a significant increase of functional plasma
ADMwhich leads to – as we hypothesize – the restoration of vas-
cular integrity (endothelial effect) and less vasodilatation (vascular
smooth muscle cell effect due to decreased concentrations of ADM
in the interstitium). Further, it is thought that adrecizumab prevents
ADM from being degraded by proteases and prolongs half-life of
ADM.72
In animal models of systemic inflammation and septic shock,
adrecizumab improved haemodynamics, renal function, sys-
temic inflammation and reduced inducible nitric oxide synthase
expression.72 Currently, adrecizumab is being evaluated in a phase
II trial in human septic shock (http://clinicaltrials.gov identifier:
NCT03085758). There were no safety concerns observed in
pre-clinical studies, as well as in two phase I studies in which
0.5, 2 and 8mg/kg were administered to healthy volunteers.72
Importantly, even though adrecizumab induced great increases
in circulating levels of ADM, this did not cause hypotension. In
a phase Ib study, where healthy subjects received an infusion of
bacterial lipopolysaccharide to induce a systemic inflammatory
response, administration of adrecizumab significantly reduced the
perception of illness/sickness, as assessed by clinical scores.73
A phase II proof of concept study in patients with worsening
heart failure and elevated bio-ADM levels after initial stabilization
is currently being considered. Patients with elevated bio-ADM have
(residual) congestion and are at high risk for clinical events, and a
heart failure readmission in particular. Adrecizumab is expected to
increase intravascular ADM and decrease interstitial ADM, since
adrecizumab may translocate ADM from the interstitium into the
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Overview of studies investigating adrenomedullin in human patients with forms of heart failure
Author (year) Intervention Condition Effects
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Nakamura67 (1997) FBF and SBF test with
intra-arterial ADM
Healthy subjects (n =10)
Patients with CHF (n =18)
↑ FBF & ↑ SBF
Effects partially NO-mediated
Impaired FBF and SBF responses in CHF
group
Nagaya68 (2000) I.v. infusion of ADM (n = 7) or
placebo (n = 6), 90min total
Patients with precapillary
pulmonary hypertension
(n =13 total)
↑ Cardiac index (44%)
↓ Pulmonary arterial pressure (32%)
↓ MAP (9mmHg), ↑ HR
↓ Plasma aldosterone (but not renin)
No effect ANP/BNP
Nishikimi69 (2009) I.v. infusion of ADM+ hANP for
12 h, followed by 12 h of
hANP
Acute heart failure patients with
dyspnoea and pulmonary
congestion (n = 7)
ADM+ hANP:
↓ MAP, PAP, systemic and pulmonary
vascular resistance
↑ Cardiac output, urine volume and
urinary sodium excretion
↓ Aldosterone, BNP, free-radical
metabolites
Kataoka70 (2010) I.v. infusion of ADM for 12 h
No placebo arm
Patients with acute myocardial
infarction before undergoing
PCI (n = 10)
During infusion, two patients showed
unstable haemodynamics
MRI 3 vs. 1month after PCI:
↑ Wall motion index, ↓ infarct size
ADM, adrenomedullin; ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; CHF, chronic heart failure; FBF, forearm blood flow; hANP, human atrial natriuretic
peptide; HR, heart rate; MAP, mean arterial pressure; MRI, magnetic resonance imaging; NO, nitric oxide; PAP, pulmonary artery pressure; PCI, percutaneous coronary
intervention; SBF, skin blood flow.
Figure 3 Mode of action of adrecizumab. Administration of
adrecizumab leads to a dose-dependent increase of plasma
adrenomedullin (ADM) bound to the administered antibody. Cir-
culating adrecizumab cannot leave the blood compartment due to
its high molecular weight (160 kDa), whereas ADM (with a much
lower molecular weight of 6 kDa) can freely cross the endothelial
barrier between the interstitium and the circulation. Binding of
ADM by adrecizumab (present in the circulation in a large excess
over ADM) prevents ADM from leaving the blood vessel, effec-
tively ‘trapping’ ADM in the circulation.
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.. circulation. The hypothesis of this study is that by improving vas-
cular integrity, it is expected that adrecizumab will decrease tis-
sue congestion and thereby improve dyspnoea, potentially reduc-
ing heart failure readmissions. However, it should be noted that
long-term effects of ADM on development and/or progression of
heart failure have never been clinically investigated. In addition,
adrecizumab itself has not been investigated in pre-clinical models
of heart failure, but only in septic shock and systemic inflammation.
Tissue congestion was never an outcome parameter in pre-clinical
studies with ADM.
Conclusions
Adrenomedullin is an endogenous hormone that is released as a
counteracting response to volume overload. Levels of ADM are
clearly increased in patients with heart failure, and higher levels
are related to more advanced heart failure and worse outcomes.
Since elevation of ADM is a feedback response to volume overload
to maintain vascular integrity and decrease vascular leakage of fluid
from the the vasculature to the tissues, measurement of ADM
might reflect tissue and pulmonary oedema. Such a measurement
might guide physicians to more intensively treat patients with heart
failure hospitalization and facilitate discharge decisions. In addition,
ADM might become a target of therapy in heart failure. The mode
of action of adrecizumab, a humanized monoclonal antibody that
binds but does not significantly inhibit ADM, might be of particular
interest, since it is assumed to translocate ADM from the intersti-
tium into the vasculature to improve vascular integrity and prevent
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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vascular leakage. A clinical study with adrecizumab is currently
being conducted in patients with sepsis and a study in hospitalized
heart failure patients is currently being prepared.
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